EXPRESSION OF SERUM ANTI-GANGLIOSIDE ANTIBODY IN PATIENTS WITH GUILLAIN-BARR SYNDROME AND ITS RELATIONSHIP WITH CLINICAL FEATURES

Introduction: In this study, we investigated the expression of serum an ganglioside antibodies in patients with Guillain-Barre syndrome (GBS) and its relationship to clinical features. Methods: A total of 104 patients with GBS were retrospectively studied and 49 patients who underwent anti-ganglioside antibody testing were analysed. Results: Serum anti-ganglioside antibodies were detected in 67.3% of GBS patients. The average age of onset was 48.8+16.1 years for anti-ganglioside antibody positivity, and 35+16.1 years for antibody negativity ( P<0.05 ). The expression ratio of anti-GM1 antibodies in acute inflammatory demyelinating polyneuropathy (AIDP) was 42.0% (P<0.05), and anti-GD1b antibodies in acute motor axonal neuropathy (AMAN) were 25% (P<0.05). Anti-GQ1b antibodies were detected in 54.5% in ataxia (P<0.05). Conclusion: The results suggest that the average age of onset was older in the anti-ganglioside positive patients than in the negative patients. Anti-GM1 antibodies were highly expressed in AIDP and anti-GD1b antibodies were significantly expressed. In addition, the anti-GM1 antibody negativity was significantly associated with cranial nerve palsy and the anti-GQIb antibodies were significantly associated with ataxia.